Detect Early. Save Lives.
Early lung cancer detection with a simple blood test. Our CIZ1B biomarker test is a non-invasive, cost effective breakthrough for detecting lung cancer at its earliest stages.
Partner with Cizzle Biotechnology PLC
Partner with Cizzle Biotechnology Advancing Early Cancer Detection Together
Guided by a mission to improve lung cancer survival, we aim to reshape the future of lung cancer diagnostics.
Strategic Partnerships & Licensing for Greater Impact:
Through strategic global partnerships, we are fast-tracking the deployment of our innovative blood test. We consider this to be the surest route to achieving our goal of earlier diagnosis, improved patient outcomes, and wider access — ultimately saving lives.
Unlocking Global Potential:
Our strategic licensing model enables rapid market deployment, bringing our innovative solution to healthcare providers globally.
We have already secured our first strategic partner in North America and will be expanding globally through additional licensing and collaborations.
Interested in partnering with us? Get in touch to explore collaboration opportunities.
Why Partner with Us? Transforming the Diagnostic Landscape
Cizzle is pioneering a new era in early lung cancer diagnosis with its patent-protected CIZ1B biomarker technology. Our diagnostic solution is non-invasive, cost-effective, and scalable, enabling earlier detection, better patient outcomes, and significant competitive advantages for our partners.
Innovation That Sets New Standards
- Revolutionary Detection: The CIZ1B biomarker is highly accurate in early-stage lung cancer detection, and could transform traditional diagnostic pathways
- Patient-Centric Design: Simple, non-invasive testing making it easier for patients and clinicians to get a fast result
- Healthcare System Benefits: Reduces strain on resources by freeing up CT scanners, minimising costly interventions, and allowing for more efficient patient care.
Clinical Validation
- CAP and CLIA Accreditation: Through our U.S. partnerships, CLIA-approved laboratories are finalising CAP accreditation.
- Clinical Validation: Validating use in leading cancer clinics through partnerships with Moffitt Cancer Center and others.
- Expanding Global Reach: Successful licensing across North America and the Caribbean, with further strategic international expansion underway
Scalable Partnerships Model:
- Efficient Market Entry: Our localised licensing strategy enables partners to deploy quickly in their regions
- Comprehensive Support: Partners will have access to implementation expertise and ongoing operational guidance
- Flexible Integration: Adaptable solutions that align with existing healthcare infrastructure
Partner with Us to Transform Cancer Detection
We are actively seeking forward-thinking partners in healthcare, biotechnology, and investment to scale our impact and revolutionise early lung cancer detection.
Beyond licensing, we collaborate across the healthcare ecosystem—from providers to insurers—to expand access, accelerate adoption, and improve patient outcomes. If you share our vision for a future where lung cancer is detected earlier and treated more effectively, let’s explore how we can work together.
Current Collaboration
Partnerships drive innovation and accelerate global adoption of our lung cancer diagnostic technology.
